<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801682</url>
  </required_header>
  <id_info>
    <org_study_id>KLI 561-B31</org_study_id>
    <nct_id>NCT02801682</nct_id>
  </id_info>
  <brief_title>NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis</brief_title>
  <acronym>NOBICS</acronym>
  <official_title>NOBICS - NOvel BIomarker In Invasive CandidiasiS/Candida Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Graz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical University of Graz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Invasive Candida infections are serious complications in immunocompromised patients including&#xD;
      those undergoing treatment for cancer but occur also in patients treated in ICUs. Survival&#xD;
      rate of invasive candidiasis is associated with early initiation of antifungal therapy (15%&#xD;
      mortality rate for candidemic patients with antifungal therapy on day 0 related to the&#xD;
      culture date of the first blood sample positive for yeasts compared to 41% for patients who&#xD;
      received antifungal therapy on day 3). Up to date, no laboratory method or clinical decision&#xD;
      rule is available for correct anticipation of invasive candidiasis which would avoid delays&#xD;
      in appropriate antifungal therapy initiation. In clinical practice culture based methods&#xD;
      (e.g. blood cultures) miss up to 50% of invasive candidiasis cases. Preemptive antifungal&#xD;
      therapy is therefore often initiated in critically ill patients after Candida has been&#xD;
      isolated from various non-sterile patient samples even without any sufficient evidence for&#xD;
      invasive candidiasis. The disadvantages of this approach include over- and undertreatment of&#xD;
      patients (up to 50% of candidemia cases are missed, and on the other hand 89% patients are&#xD;
      treated unnecessarily), increased selective pressure for the development of antifungal&#xD;
      resistance, potential risk of adverse drug reactions, and increased costs (expenses for&#xD;
      antifungal therapy account for half of the antimicrobial medication budget in tertiary care&#xD;
      hospitals). In addition, no survival benefit could be demonstrated by this strategy in ICU&#xD;
      patients.&#xD;
&#xD;
      The aim of this study is to identify biological markers to anticipate or support the&#xD;
      diagnosis of invasive candidiasis in ICU patients, to overcome current deficiencies in&#xD;
      detection of invasive candidiasis and consequently to differentiate between Candida spp.&#xD;
      colonization and invasive Candida infection. The investigators intend to examine time&#xD;
      dependent courses of potential host and pathogen derived biomarkers as well as innate or&#xD;
      acquired predispositions for invasive candidiasis; e.g. automated (1→3) ß- D- Glucan tests,&#xD;
      DNA in serum blood samples, pathogen recognition receptors and serum markers like interleukin&#xD;
      (IL)-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine,&#xD;
      composition of indigenous microbiota of gastrointestinal and lower respiratory tract and&#xD;
      skin, and risk factors for invasive candidiasis like underlying diseases and treatments. The&#xD;
      study should contribute to improved assessment of ICU patients at risk for invasive&#xD;
      candidiasis and to improved diagnosis of invasive candidiasis in ICU patients. In clinical&#xD;
      practice the reliable differentiation between infection and colonization will allow more&#xD;
      targeted antifungal therapy leading to enhanced antifungal treatment initiation on the one&#xD;
      hand (in cases of true invasive candidiasis) and to reduction of unnecessary antifungal&#xD;
      treatments and treatment costs on the other hand.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">August 2021</completion_date>
  <primary_completion_date type="Actual">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarkers indicating or excluding invasive Candidiasis</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Automated (1→3) ß- D- Glucan tests (pg/ml) DNA in serum blood samples (quantity and sequences) pathogen recognition receptors (% of cells as assessed by FACS analysis) serum markers like IL-1, IL-2, IL-6, IL-10, IL-12, IL-17A, IL-17F, IL-22, IL-23, Tryptophan, Kynurenine (quantity) composition of indigenous microbiota of gastrointestinal and lower respiratory tract and skin (comparison of detection rates and abundances of different classes or genera)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk factors for Invasive Candidiasis</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Risk factors as described in previous literature, e.g. Eggimann, Lancet Infect Dis 2003; 3: 685-702</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">200</enrollment>
  <condition>Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>Healthy Controls</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Invasive Candidiasis</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Bacterial Sepsis (Bacteremia)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>ICU patients without infectious disease</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        1. Healthy subjects&#xD;
&#xD;
          2. Patients with invasive candidiasis/Candida sepsis&#xD;
&#xD;
          3. Patients with sepsis and bacteremia&#xD;
&#xD;
          4. ICU Patients without infectious disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        ad 1:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        -subjects without any evidence of current or chronic infectious diseases&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical or radiological or laboratory evidence of current infectious disease&#xD;
             (temperature &gt;38°C, elevated CRP &gt;5mg/dl, leukocytosis &gt;11400, elevated neutrophiles)&#xD;
&#xD;
          -  antifungal therapy within 8 weeks prior to inclusion&#xD;
&#xD;
          -  immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc)&#xD;
&#xD;
          -  active haematooncological diseases&#xD;
&#xD;
          -  HIV positivity&#xD;
&#xD;
        ad 2:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        -Patients with invasive Candidias/Candida sepsis as defined in recent EORTC/MSG&#xD;
        definitions.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  glucocorticoid treatment with prednisone equivalent of ≥20mg/d&#xD;
&#xD;
          -  inherited neutrophil deficiency&#xD;
&#xD;
          -  absolute neutrophil count of ≤500cells/mm3&#xD;
&#xD;
          -  antifungal therapy within 8 weeks prior to inclusion&#xD;
&#xD;
          -  immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d,&#xD;
             methotrexate, azathioprin etc)&#xD;
&#xD;
          -  active hematooncological disease&#xD;
&#xD;
          -  HIV positivity&#xD;
&#xD;
        ad 3:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        -ICU patients with sepsis and proven bacteremia (Staph. aureus or E. coli)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Antifungal therapy within 8 weeks prior to inclusion&#xD;
&#xD;
          -  immunosuppressive therapy (glucocorticoids with prednisone equivalent of ≥20mg/d,&#xD;
             methotrexate, azathioprin etc)&#xD;
&#xD;
          -  active hematooncological disease HIV positivity&#xD;
&#xD;
        ad 4:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
        -ICU patients without invasive candidiasis as defined above, without bacteremia and without&#xD;
        clinical and laboratory markers of infection(e.g. intubated and mechanically ventilated&#xD;
        patients with stroke or CPR)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Clinical or radiological or laboratory evidence of current infectious disease&#xD;
             (temperature &gt;38°C, elevated CRP &gt;5mg/dl, leukocytosis &gt;11400, elevated neutrophiles)&#xD;
&#xD;
          -  antifungal therapy within 8 weeks prior to inclusion&#xD;
&#xD;
          -  immunosuppressive therapy (e.g. glucocorticoids, methotrexate, azathioprin, etc)&#xD;
&#xD;
          -  active haematooncological diseases&#xD;
&#xD;
          -  HIV positivity&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Krause, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Section of Infectious Diseases and Tropical Medicine, Dpt of Internal Medicine, Medical University of Graz</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Stmk</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Graz</investigator_affiliation>
    <investigator_full_name>Robert Krause, MD</investigator_full_name>
    <investigator_title>Univ.Prof.Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

